Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II study. The phase I portion of the study will determine the maximum
tolerated dose of bortezomib when administered in combination with carboplatin & docetaxel
and to determine the efficacy of the combination for patients with advanced NSCLC. Phase II
will utilize the dosage determined in the Phase I and implement regimen to determine time to
progression, overall survival, and changes in serum proteomics patterns before & after
combination therapy.